FDA Approves New Treatment for Metastatic Pancreatic Cancer

It’s been a long time coming, but a new frontline therapy for pancreatic cancer has been approved by the U.S. Food and Drug Administration (FDA). While decades of cancer research have led to innovation and new medications for myriad types of cancer, new therapies have yet to be offered for pancreatic cancer until now, giving patients who suffer from it more treatment options. NALIRIFOX, produced by Ipsen Biopharmaceuticals, is meant for treating metastatic pancreatic adenocarcinoma. It went through the FDA’s orphan drug status approval process and received approval on Tuesday. An orphan drug is intended for a rarer disease, and the program incentivizes drugmakers to produce it to make up for reduced profits....